MNKD logo

MannKind Corporation (MNKD)

$3.90

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MNKD

Market cap

$1.25B

EPS

-0.13

P/E ratio

--

Price to sales

2.69

Dividend yield

--

Beta

1.092601

Price on MNKD

Previous close

$3.76

Today's open

$3.92

Day's range

$3.80 - $4.09

52 week range

$2.23 - $6.51

Profile about MNKD

CEO

Michael E. Castagna

Employees

592

Headquarters

Danbury, CT

Exchange

NASDAQ Global Market

Shares outstanding

321640118

Issue type

Common Stock

MNKD industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MNKD

MannKind Q3 Earnings Call Highlights

MannKind NASDAQ: MNKD expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza launches gain traction.

news source

MarketBeat • Nov 6, 2026

news preview

MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript

MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 6, 2026

news preview

MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates

MannKind (MNKD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.03 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

news source

Zacks Investment Research • Nov 6, 2026

news preview

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday, November 5, 2026.

news source

GlobeNewsWire • Oct 29, 2026

news preview

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth

MannKind NASDAQ: MNKD Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF, following early safety and tolerability results that did not show the gastrointestinal issues often associated with oral nintedanib.

news source

MarketBeat • Oct 20, 2026

news preview

This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

news source

Benzinga • Oct 19, 2026

news preview

MannKind to Participate in the Chardan Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on innovation across chronic respiratory diseases at the Chardan Healthcare Conference. Management will also participate in one-on-one meetings with investors during the conference.

news source

GlobeNewsWire • Oct 14, 2026

news preview

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase 1b data for MNKD-201 in idiopathic pulmonary fibrosis, or IPF.

news source

MarketBeat • Sep 17, 2026

news preview

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

MannKind Corporation (NASDAQ:MNKD) shares are trading lower on Wednesday as traders react to the company's entry into a licensing and collaboration deal tied to an inhaled, rapid-acting GLP-1 program.

news source

Benzinga • Sep 9, 2026

news preview

¹ Disclosures

Get started with M1

Invest in MannKind Corporation

Open an M1 investment account to buy and sell MannKind Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MNKD on M1